|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIP5KL1 |
Gene summary for PIP5KL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIP5KL1 | Gene ID | 138429 |
| Gene name | phosphatidylinositol-4-phosphate 5-kinase like 1 | |
| Gene Alias | PIPKH | |
| Cytomap | 9q34.11 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | Q5T9C9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 138429 | PIP5KL1 | male-WTA | Human | Thyroid | PTC | 4.82e-02 | 8.87e-02 | 0.1037 |
| 138429 | PIP5KL1 | PTC01 | Human | Thyroid | PTC | 2.56e-04 | 1.13e-01 | 0.1899 |
| 138429 | PIP5KL1 | PTC04 | Human | Thyroid | PTC | 1.09e-02 | 9.52e-02 | 0.1927 |
| 138429 | PIP5KL1 | PTC05 | Human | Thyroid | PTC | 9.52e-04 | 1.95e-01 | 0.2065 |
| 138429 | PIP5KL1 | PTC06 | Human | Thyroid | PTC | 7.62e-07 | 1.89e-01 | 0.2057 |
| 138429 | PIP5KL1 | PTC07 | Human | Thyroid | PTC | 1.24e-09 | 1.87e-01 | 0.2044 |
| 138429 | PIP5KL1 | ATC09 | Human | Thyroid | ATC | 1.54e-13 | 5.48e-01 | 0.2871 |
| 138429 | PIP5KL1 | ATC1 | Human | Thyroid | ATC | 8.56e-13 | 6.03e-01 | 0.2878 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010563113 | Thyroid | PTC | negative regulation of phosphorus metabolic process | 219/5968 | 442/18723 | 4.47e-15 | 3.07e-13 | 219 |
| GO:0045936113 | Thyroid | PTC | negative regulation of phosphate metabolic process | 218/5968 | 441/18723 | 7.08e-15 | 4.75e-13 | 218 |
| GO:0001933113 | Thyroid | PTC | negative regulation of protein phosphorylation | 173/5968 | 342/18723 | 3.46e-13 | 1.75e-11 | 173 |
| GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
| GO:005188119 | Thyroid | PTC | regulation of mitochondrial membrane potential | 41/5968 | 74/18723 | 2.36e-05 | 2.34e-04 | 41 |
| GO:001056334 | Thyroid | ATC | negative regulation of phosphorus metabolic process | 234/6293 | 442/18723 | 2.30e-17 | 2.31e-15 | 234 |
| GO:004593634 | Thyroid | ATC | negative regulation of phosphate metabolic process | 233/6293 | 441/18723 | 3.68e-17 | 3.47e-15 | 233 |
| GO:000193333 | Thyroid | ATC | negative regulation of protein phosphorylation | 186/6293 | 342/18723 | 1.43e-15 | 1.08e-13 | 186 |
| GO:004232634 | Thyroid | ATC | negative regulation of phosphorylation | 203/6293 | 385/18723 | 5.30e-15 | 3.53e-13 | 203 |
| GO:0051881110 | Thyroid | ATC | regulation of mitochondrial membrane potential | 44/6293 | 74/18723 | 4.51e-06 | 4.94e-05 | 44 |
| GO:004001316 | Thyroid | ATC | negative regulation of locomotion | 160/6293 | 391/18723 | 1.36e-03 | 7.07e-03 | 160 |
| GO:003033616 | Thyroid | ATC | negative regulation of cell migration | 142/6293 | 344/18723 | 1.64e-03 | 8.22e-03 | 142 |
| GO:005127117 | Thyroid | ATC | negative regulation of cellular component movement | 150/6293 | 367/18723 | 1.99e-03 | 9.54e-03 | 150 |
| GO:200014617 | Thyroid | ATC | negative regulation of cell motility | 147/6293 | 359/18723 | 2.01e-03 | 9.60e-03 | 147 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIP5KL1 | SNV | Missense_Mutation | c.776G>T | p.Ser259Ile | p.S259I | Q5T9C9 | protein_coding | deleterious(0.01) | possibly_damaging(0.859) | TCGA-AC-A3QP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | |
| PIP5KL1 | SNV | Missense_Mutation | novel | c.380G>A | p.Gly127Asp | p.G127D | Q5T9C9 | protein_coding | tolerated(0.22) | benign(0.009) | TCGA-AR-A5QP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| PIP5KL1 | insertion | Frame_Shift_Ins | novel | c.56_57insTGATCCAG | p.Cys20AspfsTer39 | p.C20Dfs*39 | Q5T9C9 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| PIP5KL1 | SNV | Missense_Mutation | novel | c.648G>C | p.Glu216Asp | p.E216D | Q5T9C9 | protein_coding | tolerated(0.29) | benign(0.056) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| PIP5KL1 | SNV | Missense_Mutation | c.173N>C | p.Met58Thr | p.M58T | Q5T9C9 | protein_coding | tolerated(0.06) | benign(0.134) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIP5KL1 | SNV | Missense_Mutation | novel | c.574C>T | p.Arg192Trp | p.R192W | Q5T9C9 | protein_coding | deleterious(0.01) | possibly_damaging(0.809) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PIP5KL1 | SNV | Missense_Mutation | c.670N>A | p.Glu224Lys | p.E224K | Q5T9C9 | protein_coding | tolerated(0.12) | benign(0.051) | TCGA-AA-A02K-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD | |
| PIP5KL1 | SNV | Missense_Mutation | c.82C>T | p.Arg28Trp | p.R28W | Q5T9C9 | protein_coding | deleterious(0.02) | benign(0.432) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PIP5KL1 | SNV | Missense_Mutation | novel | c.995N>C | p.Leu332Pro | p.L332P | Q5T9C9 | protein_coding | deleterious(0.04) | probably_damaging(0.997) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PIP5KL1 | SNV | Missense_Mutation | novel | c.397N>A | p.Leu133Ile | p.L133I | Q5T9C9 | protein_coding | tolerated(1) | benign(0.078) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |